Cointime

Serenex

company

About

Serenex is a drug discovery and development company focused on oncology.

  • 11 - 50

Highlights

Total Funding Amount
$79M
Funding Rounds
4
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$8M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2000
Number Of Employee
11 - 50
Operating Status
Active

Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients.

Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$79M
Serenex has raised a total of $79M in funding over 2 rounds. Their latest funding was raised on Jun 28, 2007 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 28, 2007 Series D $26M 2 — — Detail
Oct 6, 2005 Series C $30M 1 — — Detail
Jul 30, 2004 Series Unknown $8M 1 — — Detail
Sep 13, 2002 Series B $15M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Serenex is funded by 2 investors. Seaflower Ventures and Cornel Capital Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Seaflower Ventures — Series D
Cornel Capital Partners — Series D
Cointime
เนื้อหา
บริษัท